KDR and gastric cancer: Apatinib, a powerful tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor 2, has demonstrated its safety and effectiveness as a small-molecule anti-angiogenic drug for treating advanced gastric cancer patients who have not responded to standard chemotherapy.42